Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central anxious technique, conolidine modulates alternate molecular targets. A Science Innovations review identified that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide ... https://sandrar370hov3.snack-blog.com/profile